Toward minimizing overtreatment and undertreatment of ductal carcinoma in situ in the United States

Journal of Clinical Oncology

Volumn 34, Issue 11, 2016, Pages 1172-1174

  Smith, Grace L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; HUMAN; INTRADUCTAL CARCINOMA; META ANALYSIS (TOPIC); OVERTREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; THERAPY; UNDERTREATMENT; UNITED STATES; ADJUVANT RADIOTHERAPY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; MORTALITY; SEGMENTAL MASTECTOMY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; RADIOTHERAPY, ADJUVANT;

EID: 84963743443     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.2064     Document Type: Review

References (11)

1. Correa C, McGale P, Taylor C, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010:162-177, 2010.
2. Darby S, McGale P, Correa C, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 378:1707-1716, 2011.
3. McCormick B, Winter K, Hudis C, et al: RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33:709-715, 2015.
4. Solin LJ, Gray R, Hughes LL, et al: Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33:3938-3944, 2015.
5. Silverstein MJ: The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186:337-343, 2003.
6. Punglia RS, Burstein HJ, Weeks JC: Radiation therapy for ductal carcinoma in situ: A decision analysis. Cancer 118:603-611, 2012.
7. Sagara Y, Freedman RA, Vaz-Luis I, et al: Patient prognostic score and associations with survival improvement offered by radiotherapy after breastconserving surgery for ductal carcinoma in situ: A population-based longitudinal cohort study. J Clin Oncol 34:1190-1196, 2016.
8. Solin LJ, Gray R, Baehner FL, et al: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105:701-710, 2013.
9. Ryser MD, Worni M, Turner EL, et al: Outcomes of active surveillance for ductal carcinoma in situ: A computational risk analysis. J Natl Cancer Inst 108: djv372, 2015.
10. Pan IW, Smith BD, Shih YC: Factors contributing to underuse of radiation among younger women with breast cancer. J Natl Cancer Inst 106:djt340, 2014.
11. Smith BD, Smith GL, Roberts KB, et al: Baseline utilization of breast radiotherapy before institution of the Medicare practice quality reporting initiative. Int J Radiat Oncol Biol Phys 74:1506-1512, 2009.